ahlam1399
07-27-2016, 04:02 PM
GSK outlook brightens as Brexit brings currency windfall
LONDON (Reuters) - Demand for new medicines helped GlaxoSmithKline grow earnings in the second quarter and the drugmaker is set for big gains in the rest of 2016 thanks to a weak pound, after Britain's vote to leave the European Union.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=FZILqaJeFYI:jbW8nBRGq18:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=FZILqaJeFYI:jbW8nBRGq18:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=FZILqaJeFYI:jbW8nBRGq18:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=FZILqaJeFYI:jbW8nBRGq18:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=FZILqaJeFYI:jbW8nBRGq18:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/FZILqaJeFYI
LONDON (Reuters) - Demand for new medicines helped GlaxoSmithKline grow earnings in the second quarter and the drugmaker is set for big gains in the rest of 2016 thanks to a weak pound, after Britain's vote to leave the European Union.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=FZILqaJeFYI:jbW8nBRGq18:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=FZILqaJeFYI:jbW8nBRGq18:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=FZILqaJeFYI:jbW8nBRGq18:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=FZILqaJeFYI:jbW8nBRGq18:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=FZILqaJeFYI:jbW8nBRGq18:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/FZILqaJeFYI